Impact of Increased Body Mass Index on Accuracy of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP for Diagnosis of Decompensated Heart Failure and Prediction of All-Cause Mortality
Open Access
- 1 April 2010
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 56 (4), 633-641
- https://doi.org/10.1373/clinchem.2009.129742
Abstract
Background: BNP and N-terminal proBNP (NT-proBNP) concentrations may be depressed in patients with increased body mass index (BMI). Whether increased BMI affects accuracy of these biomarkers for diagnosing decompensated heart failure (HF) and predicting outcomes is unknown. Methods: We measured BNP and NT-proBNP in 685 patients with possible decompensated HF in a free-living community population subdivided by BMI as obese, overweight, and normal weight. HF diagnosis was adjudicated by a cardiologist blinded to BNP and NT-proBNP results. We tabulated all-cause mortality over a median follow-up of 401 days and assessed marker accuracy for HF diagnosis and mortality by ROC analysis. Results: Of the 685 patients, 40.9% were obese (n = 280), 28.2% were overweight (n = 193), and 30.9% had normal BMI (n = 212). Obese patients had lower BNP and NT-proBNP compared with overweight or normal-weight individuals (P < 0.001) and decreased mortality compared with normal-weight individuals (P < 0.001). Both biomarkers added significantly to a multivariate logistic regression model for diagnosis of decompensated HF across BMI categories. NT-proBNP outperformed BNP for predicting all-cause mortality in normal-weight individuals (χ2 for BNP = 6.4, P = 0.09; χ2 for NT-proBNP = 16.5, P < 0.001). Multivariate regression showed that both biomarkers remained significant predictors of decompensated HF diagnosis in each BMI subgroup. Conclusions: In this study population, obese patients had significantly lower BNP and NT-proBNP that reflected lower mortality. BNP and NT-proBNP can be used in all BMI groups for decompensated HF diagnosis, although BMI-specific cutpoints may be necessary to optimize sensitivity.Keywords
Funding Information
- Siemens
- Roche
This publication has 28 references indexed in Scilit:
- The relationship between body mass index/body composition and survival in patients with heart failureJournal of the American Academy of Nurse Practitioners, 2008
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart FailureClinical Biochemistry, 2008
- Association of Traditional Risk Factors With Cardiovascular Death Across 0 to 10, 10 to 20, and >20 Years Follow-Up in Men and WomenThe American Journal of Cardiology, 2008
- Natriuretic PeptidesJournal of the American College of Cardiology, 2007
- Impact of Renal Disease on Natriuretic Peptide Testing for Diagnosing Decompensated Heart Failure and Predicting MortalityClinical Chemistry, 2007
- B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass SurgeryClinical Chemistry, 2006
- NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patientsEuropean Heart Journal, 2005
- The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) studyThe American Journal of Cardiology, 2005
- B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the breathing not properly multinational studyAmerican Journal of Kidney Diseases, 2003
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureThe New England Journal of Medicine, 2002